(S1 (S (S (NP (NP (NN NF-kappaB)) (CC and) (NP (NN IKK))) (PP (IN as) (NP (NP (JJ therapeutic) (NNS targets)) (PP (IN in) (NP (NN cancer)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN transcription) (NN factor) (NN NF-kappaB)) (CC and) (NP (NP (VBN associated) (JJ regulatory) (NNS factors)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NP (NP (NN IkappaB) (NN kinase)) (NNS subunits)) (CC and) (NP (NP (DT the) (NN IkappaB) (NN family) (NN member)) (NP (NN Bcl-3))))) (-RRB- -RRB-)))) (VP (VBP are) (ADVP (RB strongly)) (VP (VBN implicated) (PP (IN in) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ hematologic) (CC and) (JJ solid) (NN tumor) (NNS malignancies)))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN role)) (PP (IN for) (NP (NN NF-kappaB))) (PP (IN in) (NP (NN cancer) (NNS cells)))) (VP (VBZ appears) (S (VP (TO to) (VP (VB involve) (NP (NP (NP (NN regulation)) (PP (IN of) (NP (NN cell) (NN proliferation)))) (, ,) (NP (NP (NN control)) (PP (IN of) (NP (NN apoptosis)))) (, ,) (NP (NP (NN promotion)) (PP (IN of) (NP (NN angiogenesis)))) (, ,) (CC and) (NP (NP (NN stimulation)) (PP (IN of) (NP (NN invasion/metastasis)))))))))) (. .)))
(S1 (S (S (ADVP (JJ Consistent) (PP (IN with) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN NF-kappaB))) (PP (IN in) (NP (NN oncogenesis)))))) (VP (VBP are) (NP (NP (NNS observations)) (SBAR (IN that) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN NF-kappaB))) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN cancer) (NNS therapies))))))) (VP (VBZ leads) (PP (TO to) (NP (NP (NN tumor) (NN cell) (NN death)) (CC or) (NP (NN growth) (NN inhibition)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (JJ other) (JJ experimental) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NN NF-kappaB)) (VP (MD can) (VP (VB play) (NP (DT a) (NN tumor) (NN suppressor) (NN role)) (PP (IN in) (NP (JJ certain) (NNS settings))))))) (CC and) (SBAR (IN that) (S (NP (PRP it)) (VP (MD can) (VP (VB be) (ADJP (JJ important) (PP (IN in) (S (VP (VBG promoting) (NP (NP (DT an) (JJ apoptotic) (NN signal)) (ADJP (JJ downstream) (PP (IN of) (NP (JJ certain) (NN cancer) (NN therapy) (NNS regimens)))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (ADVP (RB appropriately)) (VP (VB move) (NP (NN NF-kappaB) (NNS inhibitors)) (PP (IN in) (NP (DT the) (NN clinic))))))) (, ,) (NP (JJ thorough) (NNS approaches)) (VP (MD must) (VP (VB be) (VP (VBN initiated) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP dictate) (NP (NP (DT the) (NN complexity)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ oncologic)) (CC and) (ADJP (JJ therapeutic))) (NNS outcomes)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN controlled) (PP (IN by) (NP (NN NF-kappaB))))))))))))))))))))) (. .)))
